Federal Psilocybin Policy: What Changed in 2025–2026 and What's Next

About This Video

This policy analysis from Psychedelics Today covers the rapidly shifting federal landscape around psilocybin and psychedelic medicines in 2025-2026. The pace of change has accelerated dramatically: the April 2026 executive order directing VA-affiliated research into psilocybin and ibogaine for veterans, FDA breakthrough therapy designations for psilocybin in multiple indications, and the political realignment that has made some Republican legislators unlikely allies in psychedelic reform.

The video begins with the historical baseline: psilocybin has been Schedule I since 1970, and federal law has been the ceiling constraining state-level programs. Oregon's Measure 109, Colorado's Proposition 122, and the growing number of municipal decriminalization resolutions have all operated in the shadow of federal prohibition. The question of whether and how federal policy might shift has enormous downstream consequences for whether state programs can scale and whether healthcare systems can integrate psilocybin therapy.

The April 2026 executive order is examined in detail. The order directs the VA and DoD to support psilocybin and ibogaine research for veterans with PTSD and TBI — stopping well short of rescheduling but representing the first formal federal endorsement of psychedelic research as a policy priority. The video explains what the order actually requires versus what advocates hoped for, and why the gap between 'research' and 'access' remains substantial.

The video closes with a realistic assessment of the rescheduling pathway: FDA approval of psilocybin for a specific indication would trigger a mandatory DEA rescheduling review, which is currently the most plausible path to Schedule II status. COMPASS Pathways' Phase 3 data, expected in late 2026 or 2027, is the most likely trigger for this process.